Post di SIGOT

Last December, I had the privilege of watching Dr Camilla Montesano present their suspect screening approach which is now a published article: https://lnkd.in/dy4Mi4Kb In the field of toxicology, Novel psychoactive substances (NPS) present a challenge in the sense that usually a standard solution is not available to develop a targeted detection and quantification method. Immediately this poses an insurmountable challenge for a Triple Quad system which is limited to MRM ratios for identification. In this case, the authors used a hybrid system, the SCIEX QTRAP 6500+ in order to perform a suspect screening for NPS in the absence of standards. To achieve this, they leveraged prior knowledge of the molecules to obtain: - retention time (RT) prediction - MRM transitions inferred from data based on known NPS - existing spectral libraries Essentially, RT prediction along with an inferred MRM allows optimization of the cycle time in order to accommodate more molecules in the screening method. It also allows for a significantly sensitive method for triggering a data dependent scan which supports the putative identification of such NPS in the absence of standards. The Enhanced Product Ion Spectra (EPI) is a hybrid scan performed on a QTRAP system that allows such a Triple Quad based system to use spectral libraries for identification. An alternative approach to this problem would be to simply use an inclusion list as the core bottleneck is the RT prediction and the existence of the spectra in library. This would allow an EMS (enhanced full scan using the ion trap) to scan for an extended list of targets. Given that this is a hybrid targeted + suspect screening, the authors solution is unique and performance wise difficult to surpass. #SCIEX #Forensics #Toxicology #LCMSMS #massspectrometry #QTRAP

Save the date! Il 17 ottobre si terrà un workshop su Pyrogens Detection organizzato da PDA Italy Chapter. La sede dell'evento sarà a Sesto Fiorentino presso lo stabilimento Eli Lilly. Per l'agenda e iscrizioni va al link: https://lnkd.in/dhxEkvBh #lal #PDA - Parenteral Drug Association #pdaitaly #formazione #elililly

💸 𝐖𝐡𝐚𝐭 𝐚𝐫𝐞 𝐭𝐡𝐞 𝐭𝐨𝐩 𝐫𝐞𝐯𝐞𝐧𝐮𝐞 𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐨𝐫𝐬 𝐟𝐨𝐫 𝐩𝐡𝐚𝐫𝐦𝐚? The pharmaceutical industry continues to demonstrate year-on-year growth in revenue. Blockbuster medicines often drive this success, and in the graphic, you can see the top three selling medicines from the pharmaceutical giants in 2024. Oncology, immunology, and cardiometabolic diseases remain the dominant therapeutic areas. Merck's Keytruda and Johnson & Johnson's Darzalex continue to lead in oncology, while Eli Lilly and Company's Mounjaro, Zepbound, and Trulicity are taking over diabetes and obesity management. 𝘞𝘩𝘢𝘵 𝘤𝘩𝘢𝘯𝘨𝘦𝘴 𝘴𝘩𝘰𝘶𝘭𝘥 𝘸𝘦 𝘦𝘹𝘱𝘦𝘤𝘵 𝘪𝘯 2025? #pharma #biotech #business #drjojo Source: Companie's Q3 reports *Some of the drugs shown on the graph might have more than one/sponsor developer. ---------- Hi! I am Joanna, and my friends call me Dr Jojo 🌸 𝐈 𝐡𝐞𝐥𝐩 𝐬𝐭𝐚𝐫𝐭𝐮𝐩𝐬 𝐚𝐧𝐝 𝐞𝐧𝐭𝐫𝐞𝐩𝐫𝐞𝐧𝐞𝐮𝐫𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐭𝐡𝐞𝐢𝐫 𝐯𝐚𝐥𝐮𝐞 𝐚𝐧𝐝 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 ♻️ Share this if you find it interesting 🔔 Follow for insights you won't want to miss 📩 DM me to increase your visibility, grow your business, and generate leads

🧐 Unveiling Janssen's AI Strategy Map! Discover Their Partnerships Reshaping Drug Discovery, Diagnostics, and Clinical Trials. For the past 3 years, The Janssen Pharmaceutical Companies of Johnson & Johnson have been immersing themselves in #AI, forging #partnerships and strategic #investments. Here's a glimpse into some of Janssen's 17 #partnerships & #initiatives: 🤝 Strategic Partnerships: ✔️ Collaborated with #XtalPi Inc. in 2022 to expedite drug development processes. In the same year, it partnered with #Paige, focusing on evaluating an AI-powered biomarker test designed to predict actionable genomic alterations in bladder cancer. ✔️ Joined forces with #ArteraAI in 2023 to personalize cancer therapies. ✔️ Teamed up with #AtroposHealth for real-world data analysis in late 2023. 💡 #Investments in #Innovation: ✔️ Backed ArteraAI for cancer therapy personalization. ✔️ Invested in #VeranaHealth to expedite insights generation from real-world data. 🚀 #InnovationHub & Initiatives: ✔️ Augmented its innovation capacity with the global innovation hub, #JLABS, providing startups access to resources and expertise from J&J. ✔️ Launched QuickFire Challenges to accelerate transformative healthcare innovations. In recent years, the healthcare and pharmaceutical sectors have undergone a significant transformation thanks to Artificial Intelligence (AI). Notably, there has been a global increase in collaborations aimed at developing and integrating AI solutions within the pharma industry. R2G's analysis delved into a total of 139 #partnerships across 10 Major #Pharmaceuticals, offering valuable insights into various #AI #UseCases and #StrategicPartnerships. Joining The Janssen Pharmaceutical Companies of Johnson & Johnson on this journey are industry leaders such as #Bayer, #BristolMyersSquibb (BMS), #Sanofi, #Pfizer, #BoehringerIngelheim, #EliLilly and Company, #AstraZeneca, #Roche, and #GSK. 🚩 You can get your free copy of "The Pharma’s Rush into AI": https://bit.ly/48tanTi #globalhealth #PharmaAI #digitalhealthstrategies #partnerships #innovation #whitepaper

Strategic Analysis: Moderna vs Pfizer in the mRNA Race At the Institute for Generative Strategy, we’ve used the innovative 6C Model to analyze the intense competition between Moderna and Pfizer in the field of mRNA vaccines and advanced therapies. This report, generated as a brief example by our advanced 6C model, highlights the most effective strategies that Moderna can adopt to secure leadership in the mRNA space. Key stratagems identified include: 1️⃣ Giving up a lesser goal to pursue the more important one: Focus on critical objectives while letting go of less essential goals. 2️⃣ Attack the opponent's nerve points: Target Pfizer’s key vulnerabilities to disrupt their dominance. 3️⃣ Seek alliances among those who do not conflict with one's interests: Build partnerships with non-competing entities to strengthen Moderna’s position. 4️⃣ Saving energy by favoring the attrition of the opponent: Let Pfizer overextend while Moderna conserves resources. 5️⃣ Perform a diversionary maneuver towards an indirect target: Use tactics that divert Pfizer's attention and resources away from key markets. By following these insights, Moderna can strategically outmaneuver Pfizer and lead the next wave of breakthroughs in mRNA therapies. #GPT #6CModel #Strategy #GenerativeStrategy #Moderna #Pfizer #mRNA